Shattuck Labs announced positive preclinical data from an IND-enabling GLP toxicology study of SL-325 in non-human primates (NHP). The data, presented at the 20th Congress of ECCO, showed no evidence of toxicity or residual agonism, indicating a favorable safety profile for the DR3 blocking antibody.
The preclinical studies demonstrated that SL-325 achieved full and durable DR3 receptor occupancy at low doses. Population pharmacokinetic (PK) modeling suggests the potential for extended dosing intervals in humans, which could enhance patient convenience.
SL-325 is a high-affinity DR3 blocking antibody being developed for inflammatory bowel disease (IBD), and these positive preclinical results support its advancement. Shattuck Labs expects to file an IND for SL-325 in the third quarter of 2025, with Phase 1 clinical trials anticipated to begin later this year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.